Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
We work with you to map out the next steps after surgery
You may feel a little nervous, however, about actually taking it
1,2 The etiology of the disease still remains uncertain, but it is suggested that congenital cases may represent melanocyte hamartomas
Phase 2 clinical trials published in the New England Journal of Medicine (2023) reported substantial reductions in body weight and improvements in glycaemic control in participants with obesity and type 2 diabetes, though these findings require confirmation in larger Phase 3 studies
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
671 Boateng-Kuffour, A
